Case of acs nstemi with moderate lv dysfunction ef 44% ; age around 65

Case of acs nstemi with moderate lv dysfunction (ef 44%) ; age around 65 s/p ptca 3 stunts ,5 months ago, on DAPT clexane and lasix post cag 2 days ago 90% stenosis of stunts in lcx and rca ; diffuse lad disease - TVD ; complained chest pain in the morning started on nikoran infusion developed hypotension ; stopped nikoran started noradrenaline ; worsening of pain again ; management strategy now ; and what possible have gone wrong with drugs

Reading File

Finding Sources

Searching PubMed

NSTEMI cardiogenic shock norepinephrine management

Finding Sources

Searching PubMed

cardiogenic shock ACS revascularization mechanical support

Reading File

Finding Sources

Searching the Web

nicorandil nikoran hypotension NSTEMI cardiogenic shock mechanism management 2024 2025

Finding Sources

Now I have enough to give a thorough, structured answer. Let me synthesize everything.

Clinical Summary and Analysis

Patient profile: 65-year-old, known triple vessel disease (TVD), EF 44% (moderate LV dysfunction), s/p PTCA with 3 stents 5 months ago. Post-CAG (2 days ago) showing 90% in-stent restenosis (ISR) in LCx and RCA stents + diffuse LAD disease. On DAPT + enoxaparin + furosemide. Developed chest pain in the morning, started nicorandil (Nikoran) infusion, then became hypotensive. Nikoran stopped, noradrenaline started. Pain worsening again.

1. What Went Wrong with Nicorandil (Nikoran)

This is the most important pharmacological error in this case.

Nicorandil mechanism: It has a dual mechanism - a nitrate-like component (venodilation, reduces preload) AND K-ATP channel opening (arterial dilation, reduces afterload). Both actions reduce blood pressure.

Why it was dangerous here:

This patient already has moderate LV dysfunction (EF 44%) and was already on furosemide (preload-depleted state post-diuresis)
He is post-CAG (2 days) - hydration status may be borderline
He is already on enoxaparin - anticoagulated, no room for aggressive cath intervention without planning
The nicorandil infusion significantly reduced preload and afterload in a heart that was already struggling with reduced filling pressures and borderline output
This precipitated hemodynamic collapse/hypotension - essentially a vasodilatory crisis on top of borderline cardiogenic compromise

The nitrate component of nicorandil in a low EF + diuretic patient = preload crash. This is a well-recognized contraindication: nitrate-based vasodilators are hazardous when patients are hypovolemic or have significant ventricular dysfunction with marginal preload. The 2024 ESC ACS guidelines specifically caution against nitrates in patients with hemodynamic instability.

Additionally: Starting noradrenaline (alpha-1 agonist) after the hypotension increases SVR (afterload) - this is the correct move for blood pressure support, but it simultaneously increases the cardiac workload and myocardial oxygen demand in a heart with already ischemic territory (90% ISR in LCx and RCA). This explains the worsening chest pain after noradrenaline - the increased afterload/wall stress in an underperfused myocardium intensifies ischemia.

2. Current Clinical Situation - What Is Happening

The patient is likely in early cardiogenic shock or pre-shock superimposed on:

Active ACS - likely ISR-related ischemia (90% stenosis LCx + RCA stents)
Ischemia-driven LV dysfunction (EF already 44%, now under further ischemic stress)
Iatrogenic hemodynamic destabilization from nicorandil
Worsening ischemia due to noradrenaline-driven increase in afterload/oxygen demand without adequate perfusion

The SCAI shock staging is relevant here: likely Stage B-C (pre-shock to classic shock), given hypotension with worsening symptoms.

3. Immediate Management Strategy

A. Hemodynamic Stabilization

Continue/titrate noradrenaline to maintain MAP ≥65 mmHg - it is correct as the first-line vasopressor in cardiogenic shock (preferred over dopamine; lower arrhythmia risk). Target SBP 90-100 mmHg minimum.
Add dobutamine - The critical missing step. Noradrenaline alone raises afterload without improving cardiac output. In a failing LV with active ischemia, you need an inotrope to augment forward flow. Dobutamine (starting at 2-5 mcg/kg/min, titrate to 10-20 mcg/kg/min) combined with noradrenaline is the standard pharmacological bridge in cardiogenic shock per Washington Manual and major guidelines.
- Caveat: Dobutamine is proarrhythmic and may cause tachycardia, which worsens ischemia - use low doses with ECG monitoring.
Hold furosemide - Do NOT give further diuretics until hemodynamics are stabilized. The patient's preload is already compromised from prior diuresis + nicorandil. Aggressive diuresis in cardiogenic shock worsens output.
Reassess fluid status - Careful fluid challenge (100-250 mL crystalloid) may be warranted if there is evidence of preload depletion (flat neck veins, dry mucous membranes, low CVP), but must be done cautiously in a patient with EF 44%.

B. Urgent Echocardiography

Bedside echo is mandatory right now - to:
- Assess current EF (may have deteriorated further)
- Evaluate for new regional wall motion abnormalities (which territories are newly ischemic)
- Rule out mechanical complications: acute MR (papillary muscle ischemia), VSD, pericardial effusion/tamponade
- Assess RV function (RCA ISR puts the RV at risk - RV shock requires different management)
- Guide fluid management (IVC collapsibility)

C. Anticoagulation and Antiplatelet

Continue enoxaparin (therapeutic) - patient is on DAPT already; do not double anticoagulate beyond current regimen without indication
Do not add GPIIb/IIIa inhibitors at this point without hemodynamic stability
Verify last enoxaparin dose timing and renal function (dose adjustment if eGFR affected - he is 65, post-contrast CAG 2 days ago, potential contrast nephropathy)

D. Mechanical Circulatory Support (MCS) - The Key Decision

Given the clinical picture of:

TVD with 90% ISR in 2 stents + diffuse LAD disease
EF 44% (declining)
Hemodynamic instability requiring vasopressors
Active ongoing ischemia

This patient needs early MCS consideration. Per Washington Manual and the 2024 ISHLT/ESC guidance:

"The use of any vasoconstrictive agents in the setting of cardiogenic shock should prompt an evaluation for mechanical circulatory support."

Options:

IABP (Intra-aortic balloon pump) - Easiest, most accessible. Reduces afterload (diastolic augmentation) and improves coronary perfusion. Best available option in most centers for TVD with cardiogenic shock. Does not provide large flow support but reduces oxygen demand.
Impella CP/2.5 - Provides active forward flow, unloads LV more powerfully than IABP. Preferred if IABP is insufficient or patient is deteriorating.
VA-ECMO - Reserved for refractory shock (SCAI Stage D-E). Provides full circulatory support but does NOT unload the LV - often combined with Impella ("ECPELLA") if LV is severely compromised.

In this patient, an IABP is the most appropriate first step given moderate LV dysfunction and the need to bridge to revascularization. It reduces afterload, reducing noradrenaline requirements and ischemic burden.

E. Revascularization - Urgent PCI

This is the definitive treatment - the underlying problem is 90% ISR in LCx and RCA stents causing active ischemia.

Strategy:

Culprit-only PCI first - Identify the culprit vessel (the one causing the acute event - likely the one with the most ischemia on echo/ECG/symptoms) and perform urgent PCI of that lesion
For TVD with cardiogenic shock: the 2019 CULPRIT-SHOCK trial data supports culprit-only PCI in the acute phase (multivessel PCI did not improve 30-day mortality and increased renal replacement therapy needs)
The LAD diffuse disease - if not occlusive/critical, can be deferred or considered for CABG after stabilization
ISR management options: Plain balloon (POBA), drug-coated balloon (DCB - preferred for ISR), or new drug-eluting stent (DES) within the old stent

F. Monitoring

Continuous ECG, pulse oximetry, arterial line for beat-to-beat BP
Urinary catheter for hourly urine output (target >0.5 mL/kg/hr)
Serial troponins, BMP (lactate, creatinine - markers of shock severity and organ perfusion)
Consider PA catheter (Swan-Ganz) if hemodynamics unclear - to guide inotrope/vasopressor titration (target PCWP 15-18, CI >2.2)

4. Summary of Drug Errors / Suboptimal Choices

Drug	What Went Wrong	Explanation
Nicorandil (Nikoran) infusion	Primary error	Dual vasodilator (nitrate + K-ATP opener) in a preload-depleted, EF 44% patient on furosemide - predictable hemodynamic collapse. Contraindicated in hypotension/borderline shock states.
Noradrenaline alone	Partial correction	Correct for BP support but raises afterload and myocardial O2 demand without improving cardiac output, thus worsening ischemia. Dobutamine must be added.
Furosemide continuation	Should be held	Ongoing diuresis when the patient is now hemodynamically unstable compounds preload depletion.
No MCS initiated	Gap in care	With vasopressors running and worsening ischemia in a TVD patient, IABP should be placed urgently as a bridge to PCI.

5. Final Priority Order (Right Now)

Stabilize BP - titrate noradrenaline + add dobutamine
Bedside echo - assess EF, RWMA, rule out mechanical complication
Hold furosemide - reassess fluid status
Place IABP - reduce afterload, improve coronary diastolic perfusion
Urgent cath lab - culprit PCI (ISR in LCx vs RCA, whichever is culprit), with drug-coated balloon or new DES
Monitor lactate, creatinine, UO - gauge shock severity
Discuss CABG for LAD diffuse disease + multivessel disease at heart team meeting post-stabilization

Key teaching point: Nicorandil is an anti-anginal that is appropriate for stable angina with preserved hemodynamics, but using it as an infusion in an unstable ACS patient with moderate LV dysfunction on diuretics is a setup for hemodynamic collapse. The subsequent noradrenaline without an inotrope creates a high-afterload, low-output state - a closed loop of worsening ischemia. The priority now is MCS + urgent revascularization.

Washington Manual of Medical Therapeutics, p. 164 (cardiogenic shock management)

If not nicorandil here what should have been considered in its place?

Finding Sources

Searching the Web

ACS NSTEMI chest pain anti-ischemic treatment alternatives nicorandil beta blocker guidelines 2024 ESC ACC

Finding Sources

Good - I have enough from the library search, guidelines data, and my clinical knowledge to give a thorough answer. Here it is:

What Should Have Been Used Instead of Nicorandil

The core principle is: reduce ischemic burden (myocardial O2 demand) without dropping blood pressure in a patient who already has moderate LV dysfunction, is on furosemide, and is hemodynamically borderline.

1. IV Beta-Blocker - The First Choice

Metoprolol (IV then oral) is the correct anti-ischemic agent here.

Mechanism of benefit in ACS chest pain:

Reduces heart rate - this is the single most powerful way to reduce myocardial O2 demand in ischemia
Reduces contractility and wall stress - further drops O2 consumption
Prolongs diastole - improves subendocardial perfusion (coronaries fill in diastole)
Reduces catecholamine-driven vasoconstriction in the ischemic zone
Has anti-arrhythmic protection (high-risk in TVD)

Dosing: IV metoprolol 2.5-5 mg over 2 minutes, can repeat every 5 minutes up to 15 mg, followed by oral metoprolol tartrate 25-50 mg. The key is to titrate to a heart rate of 60-70 bpm.

ESC/AHA Class I recommendation for beta-blockers in NSTEMI in the absence of contraindications. Both ESC and AHA/ACC guidelines rate this Class I, Level of Evidence B.

Caveat for this patient: EF is 44% - this is moderate dysfunction but not severe decompensation. As long as there is no:

Active pulmonary edema / wet rales
SBP < 90 mmHg
Heart rate < 60 bpm
Significant AV block
Severe bronchospasm

...IV beta-blockade is appropriate and beneficial. The EF of 44% alone does NOT contraindicate it. The mistake people make is withholding beta-blockers in every reduced-EF patient - it is decompensated/wet heart failure that contraindicates IV beta-blockade, not a moderately reduced EF in an otherwise compensated patient.

2. Sublingual or Low-Dose IV Nitrate - With Extreme Caution

Short-acting sublingual GTN (0.4 mg SL) can be given for immediate pain relief - it works within 1-3 minutes and has a short duration (5-10 min), allowing rapid reassessment. Unlike a continuous IV infusion, it does not commit the patient to sustained vasodilation.

If relief is confirmed and BP tolerates it (SBP >100 mmHg after each dose), a very low-dose IV GTN infusion (5-10 mcg/min) can be started with close BP monitoring.

The critical difference from nicorandil:

GTN infusion is titratable and can be stopped instantly if BP drops
Nicorandil infusion has a longer-lasting K-ATP channel component that does not reverse quickly when stopped
In a patient with borderline preload (on furosemide, post-CAG), GTN should start at the lowest dose with close monitoring - and should be completely avoided if SBP is already <100 mmHg

Always check: RCA ISR puts the right ventricle at risk. If this patient has any RV ischemia/infarct component (which is possible given 90% RCA ISR), nitrates are absolutely contraindicated - RV infarct depends entirely on preload, and any venodilation can cause catastrophic BP drop (the same mechanism as in inferior STEMI + RV involvement).

3. IV Morphine / Opioid Analgesia - Carefully

Morphine has historically been part of the "MONA" protocol. It reduces sympathetic drive, anxiety, and catecholamine surge from pain - all of which worsen ischemia. Small doses of IV morphine (2-4 mg IV) can blunt the adrenergic response to pain.

However: There is now good evidence from observational data and registries (CRUSADE, SWEDEHEART) that morphine in NSTEMI may:

Delay P2Y12 inhibitor absorption (ticagrelor/clopidogrel) via slowed gastric motility
Be associated with worse outcomes in NSTEMI (though this is likely confounding by severity)

This patient is already on DAPT, so the drug interaction point is less critical. A small dose for pain relief while beta-blocker takes effect is reasonable.

4. Supplemental Oxygen (if SpO2 < 94%)

Simple but often overlooked. Hypoxia worsens ischemia. If the patient's SpO2 is below 94%, titrated oxygen via nasal prongs or mask is indicated. However, routine high-flow oxygen in normoxic patients is not beneficial and may be mildly harmful (coronary vasoconstriction via hyperoxia-induced free radical generation) - so do not flood with oxygen if sats are adequate.

5. What to Definitively NOT Use

Drug	Why to Avoid in This Setting
Nicorandil infusion	Dual vasodilator - drops preload and afterload simultaneously; not titratable quickly; dangerous in borderline preload state
Calcium channel blockers (dihydropyridines, e.g. nifedipine)	Reflex tachycardia worsens ischemia; ESC Class III (avoid) in NSTE-ACS without beta-blocker cover
IV GTN at high dose	Profound vasodilation + preload depletion in a patient already on diuretics
PDE5 inhibitors (sildenafil)	Irrelevant here, but worth noting they are contraindicated with nitrates

The Optimal Sequence in This Patient (Retrospective)

SL GTN once - for immediate symptom relief, reassess BP in 5 minutes
IV metoprolol 2.5-5 mg - to drop heart rate to 60-70 bpm, reduce O2 demand - the most hemodynamically safe anti-ischemic intervention
Low-dose IV GTN infusion (5-10 mcg/min) only if BP tolerated SL GTN well and SBP remains >100 mmHg
Small dose IV morphine (2 mg) if pain uncontrolled despite the above
Urgent PCI planning - because in a patient with 90% ISR and TVD, no drug permanently relieves ischemia; revascularization is the definitive treatment

The bottom line: beta-blocker was the agent of choice here - hemodynamically neutral in a compensated moderate-dysfunction patient, directly addresses the mechanism of ischemia (excess heart rate and wall stress), and guideline-supported as Class I in NSTEMI. Nicorandil is a drug for stable angina with normal hemodynamics - it was the wrong tool for this situation.

This is a shared conversation. Sign in to Orris to start your own chat.